Cat. No.: HY-19989

MK-571

(Synonyms: L-660711)

34 Cited Publications

Customer Review

Based on 34 publication(s) in Google Scholar

MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D₄ (LTD₄) receptor antagonist, with K_i values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.

For research use only. We do not sell to patients.

Purity: 98.85%
CAS No.: 115104-28-4
Formula: C₂₆H₂₇ClN₂O₃S₂
Molecular Weight:515.09

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

MK-571 Chemical Structure

CAS No.: 115104-28-4

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (34)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

LTD₄

0.22 nM (Ki, In guinea pig lung)

LTD₄

2.1 nM (Ki, In human lung)

LTD₄

10.5 (pA2, on guinea pig ileum)

LTE₄

10.4 (pA2, on guinea pig ileum)

All Leukotriene Receptor Isoforms :

All LPL Receptor Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
GLC-4/ADR	IC₅₀	0.4 μM Compound: MK-571	TP_TRANSPORTER: inhibition of Daunorubicin uptake (Daunorubicin: 0.6 uM) in membrane vesicles from GLC4/ADR cells TP_TRANSPORTER: inhibition of Daunorubicin uptake (Daunorubicin: 0.6 uM) in membrane vesicles from GLC4/ADR cells	[PMID: 10188979]
HEK293	IC₅₀	4 μM Compound: MK-571	TP_TRANSPORTER: inhibition of PAH uptake (PAH: 0.1uM) in membrane vesicles from MRP2-expressing HEK cells TP_TRANSPORTER: inhibition of PAH uptake (PAH: 0.1uM) in membrane vesicles from MRP2-expressing HEK cells	[PMID: 10760098]
HEK293	IC₅₀	10 μM Compound: MK-571	TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP4-expressing HEK293 cells	[PMID: 12695538]
HEK293	IC₅₀	40 μM Compound: MK-571	TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP5-expressing HEK293 cells TP_TRANSPORTER: inhibition of 9-(2-phosphonomethoxyethyl)adenine(PMEA) efflux (PMEA: 1 uM) in MRP5-expressing HEK293 cells	[PMID: 12695538]
HEK293	IC₅₀	2.9 μM Compound: MK-571	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	4.4 μM Compound: MK-571	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	6.4 μM Compound: MK-571	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting	[PMID: 22541068]
HEK293	IC₅₀	0.06 μM Compound: MK571	Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM) Potentiation of etoposide-induced cytotoxicity against HEK293 cells assessed as etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 0.11 +/- 0.03 nM)	[PMID: 27504669]
HEK293	IC₅₀	5.22 μM Compound: MK571	Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM) Inhibition of human ABCC1 transfected in HEK293 cells assessed as potentiation of etoposide-induced cytotoxicity by measuring etoposide IC50 at 25000 nM after 72 hrs by CCK8 assay (Rvb = 38.54 +/- 5.62 nM)	[PMID: 27504669]
HEK293	IC₅₀	0.16 nM Compound: MK-571	Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 25 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM) Effect on etoposide-induced cytotoxicity against HEK293 cells by measuring etoposide IC50 at 25 uM after 72 hrs by CCK8 assay (Rvb =0.21 +/- 0.04 uM)	[PMID: 32347726]
HeLa	IC₅₀	3.3 μM Compound: MK-571	Inhibition of recombinant MRP1 expressed in human HeLa T5 cells assessed as ATP-dependent transport of [3H]para-aminohippurate Inhibition of recombinant MRP1 expressed in human HeLa T5 cells assessed as ATP-dependent transport of [3H]para-aminohippurate	[PMID: 19580319]
HL-60	IC₅₀	0.5 μg/mL Compound: MK-571	Ability to inhibit 50 nM Leukotriene C4 (LTC4) uptake into HL60/ADR membrane vesicles Ability to inhibit 50 nM Leukotriene C4 (LTC4) uptake into HL60/ADR membrane vesicles	[PMID: 10612603]
L929	IC₅₀	>100 μM Compound: MK571	Cytotoxicity against mouse L929 cells assessed as reduction in cell survival after 5 days by MTS assay Cytotoxicity against mouse L929 cells assessed as reduction in cell survival after 5 days by MTS assay	[PMID: 30351934]
MDCK	IC₅₀	>1000 nM Compound: MK-571	Inhibition of ABCC2 overexpressed in MDCK cells at 100 uM by flow cytometric-based chloromethylfluorescein-diacetate accumulation assay Inhibition of ABCC2 overexpressed in MDCK cells at 100 uM by flow cytometric-based chloromethylfluorescein-diacetate accumulation assay	[PMID: 19170519]
MDCK	EC₅₀	2.85 μM Compound: MK-571	Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation by fluorescence assay Inhibition of MRP1 expressed in MDCK cells assessed as calcein AM accumulation by fluorescence assay	[PMID: 20684594]
NCI-H69	EC₅₀	12.4 μM Compound: MK-571	Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis Modulation of MRP1 mediated drug efflux in doxorubicin-resistant human H69 cells assessed as accumulation of calcein AM incubated for 15 mins prior to calcein AM addition measured after 30 mins by fluorescence analysis	[PMID: 25311564]
Sf9	IC₅₀	2.62 μM Compound: MK-571	TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells TP_TRANSPORTER: inhibition of E217betaG uptake (E217betaG: 0.055 uM) in membrane vesicles from Mrp2-expressing Sf9 cells	[PMID: 11306690]
Sf9	IC₅₀	10 μM Compound: MK-571	Inhibition of human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles Inhibition of human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles	[PMID: 18457386]

In Vitro

MK571 (15 μM, 1 h) markedly suppresses constitutive and Ag-stimulated S1P secretion from RBL-2H3 cells and mast cells, and inhibits Fluo-3 efflux^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

RBL-2H3 cells, human LAD2 mast cells
Concentration:

15 μM
Incubation Time:

1 h
Result:

Inhibited S1P secretion by vector and SphK1 transfected RBL-2H3 cells, whereas it did not affect uptake and intracellular conversion of [3H]Sph to S1P. Inhibited Fluo-3 efflux, inhibited S1P export by LAD2 cells, and blocked Ag-stimulated release of S1P.

In Vivo

MK-571 (0-0.5 mg/kg, orally, once) produces dose-dependent inhibition of the duration of antigen-induced dyspnea in conscious sensitized rats treated with methysergide (3 μg/kg)^[1].
MK-571 (0-1 mg/kg, orally, once) blocks LTD₄- and Ascaris-induced bronchoconstriction in conscious squirrel monkeys^[1].
MK-571 (0-25 mg/kg, orally, daily, for 2 more weeks) shows reversal of hypoxic pulmonary hypertension (PH), and protects mice from hypoxic PH^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Hyperreactive rats (male and female, 200-400 g, pretreated intravenously with 3 μg/kg methysergide, 5 min before antigen chdlenge)^[1]
Dosage:

0.5, 0.15, and 0.05 mg/kg
Administration:

Orally, once, 1 or 4 h before challenge
Result:

Produced dose-dependent inhibition of the duration of antigen-induced dyspnea, with ED₅₀ values of 0.13 (95% confidence interval (CI), 0.03-0.62) and 0.11 (95% CI, 0.009-1.47) mg/kg, respectively. MK-571 was even more active when administered orally as a suspension in 1% Methocel (4 h pretreatment), with an ED₅₀ of 0.068 (95% CI, 0.83-0.14) mg/kg.

Animal Model:

Csnscisus squirrel msnkeys^[1]
Dosage:

0.1, 0.5, and 1 mg/kg
Administration:

Orally, once, 2 h prior to challenge with Ascaris antigen
Result:

Produced significant inhibition of the bronchoconstriction at 0.5 mg/kg, produced significant inhibition of the increases in R_L and decreases in C_dyn at 1 mg/kg.

Animal Model:

FVB (Friend virus B-type) mice (Mrp4^–/– and WT, 6 weeks old, exposed to chronic hypoxia (10% O₂) in a ventilated chamber for 28 days)^[2]
Dosage:

0, 5, and 25 mg/kg
Administration:

Orally, daily, for 2 more weeks, maintain in hypoxic conditions
Result:

Showed reversal of hypoxic pulmonary hypertension (PH), and mice were protected from hypoxic PH. MK-571-treated mice displayed lower RVSP and Fulton index and a decrease in the medial thickening of small pulmonary arteries and arterioles.

Chemical Information

CAS No. 115104-28-4
Appearance Solid
Molecular Weight 515.09
Formula C₂₆H₂₇ClN₂O₃S₂
Color Off-white to light yellow
SMILES

O=C(O)CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O
Synonyms

L-660711
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (34)

All Cell Proliferation/Viability AssayBio/Physico-chemical AssayCell Imaging/StainingIFWBIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nature

Catabolism of extracellular glutathione supplies cysteine to support tumours. [Abstract]

2026 May;653(8115):933-941. PMID: 41851454
Cell

Prolonged sleep deprivation induces a cytokine-storm-like syndrome in mammals. [Abstract]

2023 Dec 7;186(25):5500-5516.e21. PMID: 38016470

MK-571 purchased from MedChemExpress. Usage Cited in: Cell. 2023 Dec 7;186(25):5500-5516.e21. [Abstract]

Survival curves for mice subjected to SD (SR means 48 h of recovery after SD) with oral administration of MK-571 sodium (0.1 mg/mL) (n = 10) in the drinking water compared with water controls (n = 10). The results showed that MK-571 sodium protected against SD-induced mortality.
Cancer Res

Targeted KRASG12V Degradation in vivo Elicits Lung Adenocarcinoma Regression with Subsequent Relapse from Dysregulated Proteolysis. [Abstract]

2026 May 27:10.1158/0008-5472.CAN-25-5172. PMID: 42200804
Nat Commun

ABCC1 and glutathione metabolism limit the efficacy of BCL-2 inhibitors in acute myeloid leukemia. [Abstract]

2023 Sep 19;14(1):5709. PMID: 37726279
Adv Sci (Weinh)

Fusidic Acid Reverses Chemoresistance in Breast Cancer via Targeting DDX6 to Downregulate GSK-3β/β-Catenin Signaling. [Abstract]

2025 Aug 4:e04680. PMID: 40757496
Sci Adv

SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition. [Abstract]

2024 Dec 13;10(50):eadq4274. PMID: 39661665

MK-571 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

Cells were treated with the ABCC1 inhibitor MK-571 sodium (10 μM) and MRTX849 for 3 days, followed by CCK-8 assays. The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.

MK-571 purchased from MedChemExpress. Usage Cited in: Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]

Cells were treated with 1 μM MRTX849 for 6 hours or with 10 μM MK-571 sodium for 24 hours, followed by 1 μM MRTX849 for 6 hours. Intracellular MRTX849 accumulation was quantified using LC-MS/MS (Student’s t test). The results showed that MK-571 sodium improved the efficacy of MRTX849 in two resistant cells.
Free Radic Biol Med

Mifepristone protects acetaminophen induced liver injury through NRF2/GSH/GST mediated ferroptosis suppression. [Abstract]

2024 Jun 19:S0891-5849(24)00531-8. PMID: 38906233

MK-571 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2024 Jun 19:S0891-5849(24)00531-8. [Abstract]

HT1080 and HUH7 cells were pretreated with Verapamil (20 μM) or MK-571 sodium (40 μM) for 2 h and then treated with DMSO or RU486 (5 μM) together with concentration gradient of RSL3 (0–10 μM) for 24 h. Cell viability was measured by CCK-8 (n = 3).
Food Res Int

Hydroxypropyl-β-cyclodextrin as a co-delivery vehicle for synergistically enhancing fucoxanthin oral bioavailability through dual regulation of SR-B1 and ABCB1 transporters. [Abstract]

2026 Mar 31:228:118352. PMID: 41703824
Biomed Pharmacother

Interplay of drug transporters P-glycoprotein (MDR1), MRP1, OATP1A2 and OATP1B3 in passage of maraviroc across human placenta. [Abstract]

2020 Sep;129:110506. PMID: 32768979

MK-571 purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2020 Sep;129:110506. [Abstract]

MK-571 (50 μM, 10 min) increased the accumulation of [3H]-MVC in BeWo cells.
Biomed Pharmacother

Intestinal absorption mechanisms of araloside A in situ single-pass intestinal perfusion and in vitro Caco-2 cell model. [Abstract]

2018 Oct:106:1563-1569. PMID: 30119231
Cell Death Discov

Generation of a conditional cellular senescence model using proximal tubule cells and fibroblasts from human kidneys. [Abstract]

2024 Aug 14;10(1):364. PMID: 39143064

MK-571 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Aug 14;10(1):364. [Abstract]

MK-571 (5 μM, 30 min) increased the fluorescence intensity of DOX-inducible CD10⁺ PTEC CMFDA metabolites.
Arch Toxicol

In vitro function and in situ localization of Multidrug Resistance-associated Protein (MRP)1 (ABCC1) suggest a protective role against methyl mercury-induced oxidative stress in the human placenta. [Abstract]

2020 Nov;94(11):3799-3817. PMID: 32915249

MK-571 purchased from MedChemExpress. Usage Cited in: Arch Toxicol. 2020 Nov;94(11):3799-3817. [Abstract]

The MRP1 inhibitor MK-571 sodium (50 µM; 1 h) decreased A–B MeHg transport in MDCKII-MRP1 cells.
Int J Nanomedicine

The Optimization Design Of Lactoferrin Loaded HupA Nanoemulsion For Targeted Drug Transport Via Intranasal Route. [Abstract]

2019 Nov 27;14:9217-9234. PMID: 31819426
Pharmaceutics

Study on the Effect of Pharmaceutical Excipient PEG400 on the Pharmacokinetics of Baicalin in Cells Based on MRP2, MRP3, and BCRP Efflux Transporters. [Abstract]

2024 May 29;16(6):731. PMID: 38931853
Commun Biol

Activation of Nrf2/HO-1 signaling pathway exacerbates cholestatic liver injury. [Abstract]

2024 May 23;7(1):621. PMID: 38783088
CNS Neurosci Ther

Multiple drug transporters contribute to the brain transfer of levofloxacin. [Abstract]

2023 Jan;29(1):445-457. PMID: 36253925
Int J Mol Sci

LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]

2026 Mar 13;27(6):2646. PMID: 41898509
J Drug Deliv Sci Technol

2025 May.
Eur J Pharm Sci

Effect of budesonide on pulmonary activity of multidrug resistance-associated protein 1 assessed with PET imaging in rats. [Abstract]

2023 May 1:184:106414. PMID: 36858275
Toxicology

In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]

2025 Jun 3:154210. PMID: 40473197

MK-571 purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Jun 3:154210. [Abstract]

MK-571 (5 μM, 1 h) dilates the bile canalicular area in HepaRG cells.

MK-571 purchased from MedChemExpress. Usage Cited in: Toxicology. 2025 Jun 3:154210. [Abstract]

MK-571 (5 μM, 6 h) reduced the expression of NTCP, BSEP, and MRP3 in HepaRG cells.
Drug Metab Dispos

Activation of pregnane X receptor-organic anion transporting polypeptide 1a/b /P-glycoprotein/multidrug resistance protein 2 axis mediates the accelerated blood and liver clearance of PEGylated liposomes. [Abstract]

2025 Nov;53(11):100172. PMID: 41106060
Brain Res Bull

Ether lipid transfer across the blood-brain and placental barriers does not improve by inactivation of the most abundant ABC transporters. [Abstract]

2022 Oct 15:189:69-79. PMID: 35981629
Regul Toxicol Pharmacol

Characterization of in vitro Mrp2 transporter model based on intestinal organoids. [Abstract]

2019 Nov:108:104449. PMID: 31449916
Viruses

Hepatitis C Virus-Induced FUT8 Causes 5-FU Drug Resistance in Human Hepatoma Huh7.5.1 Cells. [Abstract]

2019 Apr 24;11(4):378. PMID: 31022917
Cancer Res Commun

Inhibition of NEK2 Promotes Chemosensitivity and Reduces KSHV-positive Primary Effusion Lymphoma Burden. [Abstract]

2024 Apr 9;4(4):1024-1040. PMID: 38592451
J Pharm Biomed Anal

Transport and metabolic profiling studies of amentoflavone in Caco-2 cells by UHPLC-ESI-MS/MS and UHPLC-ESI-Q-TOF-MS/MS. [Abstract]

2020 Sep 10;189:113441. PMID: 32615340
3 Biotech

Triple regulation of oxidative-acetylation cycling pathways in COPD glucocorticoid resistance by HuaTanJiangQi capsules. [Abstract]

2025 Apr;15(4):72. PMID: 40060290
Toxicol Lett

SOD2 promotes the expression of ABCC2 through lncRNA CLCA3p and improves the detoxification capability of liver cells. [Abstract]

2020 Jul 1;327:9-18. PMID: 32201199
J Appl Toxicol

Oleanolic acid induces hepatic injury by disrupting hepatocyte tight junction and dysregulation of farnesoid X receptor-mediated bile acid efflux transporters. [Abstract]

2024 Nov;44(11):1725-1741. PMID: 39030772
Eur J Drug Metab Pharmacokinet

The ATP-Binding Cassette Transporter-Mediated Efflux Transport of Ganciclovir at the Blood-Brain Barrier. [Abstract]

2024 Sep;49(5):609-617. PMID: 38963639
Eur J Drug Metab Pharmacokinet

Acyclovir Brain Disposition: Interactions with P-gp, Bcrp, Mrp2, and Oat3 at the Blood-Brain Barrier. [Abstract]

2022 Mar;47(2):279-289. PMID: 35112329
Pharmacol Res Perspect

The pharmaceutical excipient PEG400 affect the absorption of baicalein in Caco-2 monolayer model by interacting with UDP-glucuronosyltransferases and efflux transport proteins. [Abstract]

2022 Feb;10(1):e00928. PMID: 35148019
Xenobiotica

The potential role of human multidrug resistance protein 1 (MDR1) and multidrug resistance-associated protein 2 (MRP2) in the transport of Huperzine A in vitro. [Abstract]

2020 Mar;50(3):354-362. PMID: 31132291
Eberhard Karls Universität Tübingen

2022 Feb.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (194.14 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9414 mL

9.7070 mL

19.4141 mL

5 mM

0.3883 mL

1.9414 mL

3.8828 mL

10 mM

0.1941 mL

0.9707 mL

1.9414 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Jones TR, et al. Pharmacology of L-660,711 (MK-571): a novel potent and selective leukotriene D₄ receptor antagonist. Can J Physiol Pharmacol. 1989 Jan;67(1):17-28. [Content Brief]

[2]. Hara Y, et al. Inhibition of MRP4 prevents and reverses pulmonary hypertension in mice. J Clin Invest. 2011 Jul;121(7):2888-97. [Content Brief]

[3]. Mitra P, et al. Role of ABCC1 in export of sphingosine-1-phosphate from mast cells. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16394-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.9414 mL	9.7070 mL	19.4141 mL	48.5352 mL
	5 mM	0.3883 mL	1.9414 mL	3.8828 mL	9.7070 mL
	10 mM	0.1941 mL	0.9707 mL	1.9414 mL	4.8535 mL
	15 mM	0.1294 mL	0.6471 mL	1.2943 mL	3.2357 mL
	20 mM	0.0971 mL	0.4854 mL	0.9707 mL	2.4268 mL
	25 mM	0.0777 mL	0.3883 mL	0.7766 mL	1.9414 mL
	30 mM	0.0647 mL	0.3236 mL	0.6471 mL	1.6178 mL
	40 mM	0.0485 mL	0.2427 mL	0.4854 mL	1.2134 mL
	50 mM	0.0388 mL	0.1941 mL	0.3883 mL	0.9707 mL
	60 mM	0.0324 mL	0.1618 mL	0.3236 mL	0.8089 mL
	80 mM	0.0243 mL	0.1213 mL	0.2427 mL	0.6067 mL
	100 mM	0.0194 mL	0.0971 mL	0.1941 mL	0.4854 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MK-571

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Orally Active Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) MK-571

All Leukotriene Receptor Isoforms

All LPL Receptor Isoforms

Biological Activity

Chemical Information

Publications (34)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK-571

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Orally Active Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) MK-571

All Leukotriene Receptor Isoforms

All LPL Receptor Isoforms

Biological Activity

Chemical Information

Publications (34)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MK-571 Related Classifications

Cat. No.: HY-19989